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Background: Atrial fibrillation (AF) produces a hypercoagulable state. Via stimulation 
of protease-activated receptors (PARs) coagulation factors provoke pro-fibrotic, pro-
hypertrophic, and pro-inflammatory responses in a variety of tissues. We studied the 
effects of thrombin on cardiac cells and tested whether inhibition of coagulation could 
attenuate remodeling in goats with AF. 
Methods and results: In isolated rat cardiac fibroblasts, thrombin enhanced the 
phosphorylation of the pro-fibrotic signaling molecules Akt and Erk, and increased 
expression of TGFβ1 (2.7-fold) and the pro-inflammatory factor monocyte chemo-
attractant protein-1 (6.1-fold). Thrombin also increased the incorporation of 3H-proline, 
suggesting enhanced collagen synthesis by fibroblasts (2.5-fold). All effects could be 
attenuated by the thrombin inhibitor dabigatran. In 6 goats with persistent AF treated 
with nadroparin, targeting Factor Xa and thrombin, AF-induced a-smooth muscle 
expression, endomysial fibrosis and the complexity of the AF substrate were less 
pronounced than in control animals (maximal conduction time 23.3 ± 3.1 ms in control 
versus 15.7 ± 2.1 ms in nadroparin, p<0.05). 
Conclusion: The hypercoagulable state during AF causes pro-fibrotic and pro-
inflammatory responses in cardiac fibroblasts. In AF goats, nadroparin attenuated atrial 
fibrosis and the complexity of the AF substate. Inhibition of coagulation might prevent 















































While the observation that AF causes activation of blood coagulation has been made decades 
ago, far less is known about the effect of activated blood coagulation on atrial remodeling 
and on the progression of AF. The discovery of protease-activated receptors (PARs) in the 
early 1990s and the identification of multiple coagulation proteases (i.e. clotting factors) as 
their main natural ligands triggered intense research on non-hemostatic functions of the 
coagulation cascade.1-3 It was demonstrated that activation of PARs by coagulation factors 
can cause vascular alterations, profibrotic effects and inflammation.1-3
PARs belong to the seven membrane spanning G-protein coupled receptors superfamily 
and are expressed in many different cell types throughout the body.4,5 There are 4 isoforms 
(PAR1 to PAR4) that differ in their expression levels in various cell types and their downstream 
signaling.6 PAR1 and PAR2 are the most important isoforms in the heart.7 Thrombin, an 
important effector of the coagulation cascade, is capable of activating PAR1, PAR3 and PAR4 
and Factor Xa is capable of activating PAR1 and PAR2.
PAR-1 is expressed in myocytes, fibroblasts, endothelial cells and smooth muscle cells.4 
Its expression is elevated in patients with ischemic heart disease or heart failure.8,9 PAR-
1 activation leads to myocyte hypertrophy,6,7 and proliferation of fibroblasts.10,11 Mice 
overexpressing PAR-1 develop cardiac hypertrophy and dilated cardiomyopathy.12 In 
contrast, PAR1 deficiency was protective in a mouse model of ischemia-reperfusion.12 
PAR2 is expressed by myocytes, smooth muscle cells and endothelial cells but its 
expression by fibroblasts is uncertain.4 In myocytes, PAR2 activation leads to MAP-Kinase 
activation and cellular hypertrophy.7 PAR2 deficiency leads to reduced infarct sizes in 
ischemia-reperfusion models and reduced inflammatory responses.8
Also outside the heart, PARs are involved in many disease processes. An important role 
of PARs has been implicated in many fibro-proliferative diseases such as fibrosis of skin, 
lung, and liver.13-15
As inflammatory changes, tissue fibrosis, and cellular hypertrophy significantly 
contribute to loss of electrical conductivity between myocytes and thus conduction 
disturbances in dilated and fibrillating atria16 we hypothesize that the hypercoagulable state 
during AF promotes structural remodeling in the atria and contributes to the development 
of a substrate for AF. We aimed to investigate whether activated coagulation, via thrombin 
stimulation, could induce atrial fibroblast and atrial and ventricular cardiomyocyte 
remodeling. In addition, it was investigated whether the specific thrombin antagonist 
dabigatran could attenuate these changes in vitro and whether nadroparin, targeting Factor 
















































Isolation and culture of adult rat atrial fibroblasts
Atria of adult rats were excised and placed in ice-cold Krebs Henseleit (KH) buffer (117.5 mM 
NaCl, 5.60 mM KCl, 1.18 mM MgSO
4




, 2.52 mM CaCl
2
, 25 mM NaHCO
3
 
11.1 mM Glucose). Atria were minced into small pieces and subjected to periods of digestion 
with 0.15 mg/ml Liberase TM (Roche Diagnostics GmbH, Mannheim, Germany) in KH buffer 
supplemented with 10 mM Hepes and 20 μg/mL DNase for 10 min by constant stirring. The 
first digestion was discarded. Cells from the digestions were pooled, filtered and centrifuged. 
The pellet was resuspended in DMEM (Lonza, Verviers, Belgium) with 10% FCS and penicillin-
streptomycin (50 U/mL and 50 mg/mL, respectively) (Invitrogen Corporation, Breda, The 
Netherlands) and seeded on uncoated 6 cm dishes. This procedure was based on methods 
described by Voloshenyuk et al. and Takeda et al.17,18 The next day non-adherent cells were 
removed by washing with PBS. Cells were cultured at 37°C under 5% CO
2
 in DMEM with 
10% FCS and 1% penicillin-streptomycin (50 U/mL and 50 mg/mL, respectively) (Invitrogen 
Corporation, Breda, The Netherlands). Medium was changed every 2-3 days. At confluence 
cells were split using 0.05% trypsin-EDTA (Life technologies, Bleiswijk, The Netherlands) 
and left again until confluence was reached. Then, cells were trypsinized and counted. Cells 
were seeded at a density of 15000 cells/cm2. The next day, cells were serum starved for 
24 hr before experiments were carried out. All experiments are performed with cells from 
passage 2. To determine phenotype, cells were stained for the fibroblast markers vimentin 
(Santa Cruz Biotechnology, Heidelberg, Germany) and prolyl 4-hydroxylase subunit beta 
(P4HB, Novus Biologicals, Littleton, CO, USA) and for smooth muscle actin (Dako, Heverlee, 
Belgium) to determine smooth muscle cells and myofibroblasts. Cells were found positive 
for vimentin and P4HB and part of the cells were positive for smooth muscle actin, indicative 
of differentiation towards myofibroblasts. Less than 5% of the cells were negative for P4HB. 
Isolation and culture of neonatal rat atrial cardiomyocytes
Neonatal rat atrial and ventricular cardiomyocytes (NRAMs and NRVMs) were isolated and 
cells were cultured, as described previously.19,20 In short, the hearts of 1–3-day old Sprague 
Dawley rats were excised and transferred in a tube with cold calcium- and bicarbonate-
free Hanks with Hepes solution (CBFHH) (137 mmol/L NaCl, 5.36 mmol/L KCl, 0.81 mmol/L 
MgSO
4








 and 20 mmol/L 
HEPES, pH 7.4). Atria and ventricles were separated and cardiomyocytes were isolated by 
successive rounds of stirring and pipetting the tissue up and down in CBFHH supplemented 
with 1.5 mg/mL trypsin (BD Biosciences, Breda, The Netherlands) and 20 μg/mL DNase. 
The cell suspension was preplated on regular polystyrene dishes for 45 min to enrich for 
cardiomyocytes. Subsequently, the cardiomyocytes were counted and seeded on cell culture 
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Cardiomyocytes were cultured for 24 hours at 37°C under 5% CO
2
 in MEM and 
supplemented with sodium bicarbonate for 5% CO
2
, 25 mmol/L Hepes (Invitrogen 
Corporation, Breda, The Netherlands), 1.5 mmol/L vitamin B12, 5% FCS, 0.1 mmol/L BrdU 
and penicillin-streptomycin (50 U/mL and 50 mg/mL, respectively) (Invitrogen Corporation, 
Breda, The Netherlands). The cells were then cultured in medium without serum and 
BrdU but supplemented with transferrin (10 μg/mL), insulin (10 μg/mL) and bovine serum 
albumin (BSA) (1 mg/mL) for 24 hrs before the experiments were performed. 
All animal studies were conducted in accordance with the NIH Guide for the Care and 
Use of Laboratory Animals and approved by the Committee for Animal Experiments of the 
University of Groningen.
Cell stimulation
Cells were stimulated with 0.00001 units/ml up to 0.5 units/ml thrombin from human plasma 
(Diagnostica Stago S.A.S, Asnières sur Seine, France). Dabigatran (Boehringer Ingelheim) was 
added 30 min before addition of thrombin. To investigate whether the responses induced 
via thrombin were dependent of PAR1 we used PAR1 antagonists, 30-100 μM RWJ56110 
(Tocris Bioscience, Bristol, United Kingdom) and 1 μM SCH79797 dihydrochloride (Tocris 
Bioscience, Bristol, United Kingdom). Furthermore the PAR1 blocking antibody ATAP2 (Santa 
Cruz Biotechnology, Heidelberg, Germany) was used at 10 μg/ml. The PAR1 receptor agonist 
Trap-14 (Bachem, Bubendorf, Switzerland) was used as a positive control.
Western blotting
Proteins from whole cell lysates were isolated using radioimmuno-precipitation assay 
buffer (0.5% sodium deoxycholate, 0.1% sodium dodecylsulfate (SDS) and 1% Igepal ca-
630 in TBS) with a protease inhibitor cocktail (Roche Diagnostics Corp., Indianapolis, 
IN, USA), a phosphatase inhibitor cocktail, PMSF (1 mmol/L) (Roche Diagnostics Corp., 
Indianapolis, IN, USA) and sodium vanadate (15 mmol/L). SDS sample buffer was added 
and samples were denaturized at 99°C for 5 min. Proteins were separated by sodium 
dodecyl sulfate-polyacrylamide gel, transferred to PVDF membranes (Bio-Rad, Veenendaal, 
The Netherlands) and blocked with 5% milk. Blots were incubated with antibodies against 
phospho-Erk (E-4) (Santa Cruz Biotechnology, Heidelberg, Germany), phospho-Akt (Ser473) 
(D9E) or phospho-p38 (Thr180/Tyr182) (both Cell Signaling Technology, Danvers, MA, 
USA). The membranes were stripped (stripping buffer containing 2% SDS, 100 mmol/L 
β-mercaptoethanol and 62.5 mmol/L Tris buffer) for 30 min at 55°C, washed and incubated 
with the corresponding antibody detecting the total protein amount, i.e. total p44/42 MAPK 
(Erk1/2) (137F5) and Akt (C67E7) and p38 (all three Cell Signaling Technology, Danvers, MA, 
USA). After that, membranes were reprobed with GAPDH antibodies (Fitzgerald Industries 
International, Acton, MA, USA). Signals were detected using ECL (Perkin Elmer, Waltham, 
MA, USA) and quantified by densitometry with the ImageQuant LAS 4000 (GE Healthcare 
Europe GmbH , Diegem, Belgium). Protein levels were expressed relative to the respective 














































The Nucleospin II kit (Macherey-Nagel, Düren, Germany) was used to isolate total RNA. Total 
RNA was converted to cDNA by the QuantiTect Reverse Transcription kit (Qiagen, Venlo, 
The Netherlands). Gene expression was measured with Absolute QPCR SYBR Green ROX 
Mix (Abgene, Epsom, United Kingdom) in the presence of 7.5 ng cDNA and 200 nM forward 
and reverse primers. qRT-PCR was performed on the Biorad CFX384 (Biorad, Veenendaal, 
The Netherlands). The initial denaturation and activation of the DNA polymerase (95°C for 
3 min) was followed by 35 cycles with denaturation for 15 s at 95°C and annealing and 
elongation for 30s at 60°C followed by a melt curve. Gene expression levels were corrected 
for ribosomal protein, large, P0 (36b4) reference gene expression and values were expressed 
relative to the respective control group of each experiment. Primers used included: smooth 
muscle actin forward caccatcgggaatgaacg, smooth muscle actin reverse tgcctgggtacatggtag, 
transforming growth factor beta 1 (TGFβ1) forward aagaagtcacccgcgtgcta, TGFβ1 
reverse tgtgtgatgtctttggttttgtca, interleukin 6 (IL6) forward aacagcgatgatgcactgtc, IL6 
reverse tccaggtagaaacggaactc, monocyte chemoattractant protein 1 (MCP-1) forward 
ccgactcattgggatcatctt, MCP-1 reverse tgtctcagccagatgcagttaat, protease activated receptor 
(PAR)1 forward ttcctggcagtggtgtaccc, PAR1 reverse cgtggcaggtggtgatgttg, PAR2 forward 
tgggaggtatcacccttctg, PAR2 reverse gcgtgtccaatctgccaatc, PAR3 forward gggttaggctgctgtttctg, 
PAR3 reverse tagttgtggtggctcctgtc, PAR4 forward atgctcgggttcagcatcag, PAR4 reverse 
cctcgtggattaggcttgtc, atrial natriuretic peptide (ANP) forward atgggctccttctccatcac, ANP 
reverse tctaccggcatcttctcctc, brain natriuretic peptide (BNP) forward acaatccacgatgcagaagct, 
BNP reverse gggccttggtcctttgaga, skeletal α-actin forward gggcaggtcatcaccatc, skeletal 
α-actin reverse tacaggtccttcctgatgtc, 36b4 forward gttgcctcagtgcctcactc and 36b4 reverse 
gcagccgcaaatgcagatgg.
Proline incorporation
Cells were grown in 12 well plates and serum starved for 24 hr. L-[2,3,4,5-3H]Proline (Perkin 
Elmer, Groningen, The Netherlands) was added to all wells at a concentration of 1 μCi/ml 
directly after adding thrombin. Cells were cultured for an additional 24 hr. Afterwards cells 
were washed twice with PBS and 1 ml of cold 5% TCA was added, this was kept at 4°C for 
1 hr. Subsequently, following a TCA wash and a PBS wash, proteins were solubilized with 
0.5M NaOH for 1 hr at room temperature. Proteins were collected in scintillation tubes and 
4 ml of Ultima Gold XR scintillation liquid (Perkin Elmer, Groningen, The Netherlands) was 
added. The amount of radioactivity (CPM) was determined by a LS6500 Beckman Coulter 
scintillation.
Immunofluorescence and proliferation
Cells were fixed in 4% paraformaldehyde for 10 min on ice and washed with PBS. Proliferaton 
was detected using the CyQuant cell proliferation assay kit (Invitrogen – molecular probes, 
Eugene, OR, USA) according to the manufactures’ instruction. To confirm that the cells were 















































Animal model of AF
An atrial endocardial pacemaker lead (Medtronic Capsurefix®) was implanted in the 
right atrial appendage in all goats. The pacemaker lead was connected to an implanted 
neurostimulator (Medtronic Itrel®) and AF was maintained by repetitive 50 Hz burst pacing 
at 3 times threshold (1 s on/1 s off, remaining weeks 1s/min). The animals were treated 
with nadroparin (subcutaneous injections, 150 IU/kg, twice daily; n = 6) or saline (n = 5) for 
4 weeks followed by an open chest experiment. Nadroparin is an anticoagulant with anti-
Factor Xa and anti-thrombin activity, with a stronger effect on Factor Xa. 
Animals were anesthetized with sufentanyl (6 μg/kg/h), midazolam (0.8 mg/kg/h) 
and pancuronium (0.3 mg/kg/h). After left-sided thoracotomy, mapping was performed 
as described recently.21 Atrial fibrillatory conduction was recorded for 10s in each animal 
using a spoon shaped epicardial mapping tool (12.8 cm2, 2.4mm inter-electrode distance) 
which was placed on the left atrial free wall. A silver plate in the thoracic cavity served as 
indifferent electrode. 
Unipolar signals were recorded using a custom made 256-channel mapping amplifier 
(bandwidth 0.1- 408 Hz, sampling rate 1 kHz, resolution 16 bits) and stored for offline 
analysis. Atrial biopsies were taken for histological analysis.
Analysis of AF conduction
Local activation times were identified as points of maximum negative dV/dt in each unipolar 
electrogram. Fibrillation waves were defined as areas surrounded by lines of block or fusion 
everywhere along their boundaries within the mapping array as described earlier.22,23 
Conduction block was defined as conduction time between neighboring electrodes larger 
than 8 ms (or more than 12 ms in case of oblique electrodes) equivalent to a conduction 
velocity of <20 cm/s. All resulting semi-automatic endo-epicardial wavemaps were inspected 
and edited by two independent investigators.
Histology
After electrophysiological studies, hearts were excised, fixed in buffered 4% formaldehyde 
and embedded in paraffin for histological evaluation. Tissue sections of 5 μm were fixed 
at 56°C overnight, de-paraffinized and rehydrated. To determine myocyte diameters and 
endomysial fibrosis, left atrial sections were stained with hematoxylin and eosin, and 
photographs were taken at 400x magnification. In each goat, the diameter of the atrial 
myocytes was measured in 30-35 myocytes per goat, with the nucleus in plane of the section. 
Endomysial fibrosis was defined as connective tissue separating individual myocytes within 
bundles. The width of endomysial tissue septa was quantified as the distance between 















































Data are expressed as mean values ± standard error of the mean (SEM). Comparisons 
between two groups were done using a Student’s t-test, comparison between multiple 
groups were done using one-way analysis of variance (ANOVA) with post hoc Dunnett 
correction. All analyses were done using IBM SPSS Statistics (Version 20, SPPS Inc., Chicago, 




In neonatal atrial and ventricular cardiomyocytes and adult atrial fibroblasts PAR1 mRNA 
expression could be detected by real time PCR, low mRNA levels of PAR2 and PAR3 could 
be measured and PAR4 expression could only be detected in low amounts in atrial and 
ventricular cardiomyocytes. Expression of PAR1 was more pronounced in fibroblasts 
compared to cardiomyocytes.
Atrial fibroblasts were treated with increasing concentrations of thrombin. Stimulation 
with thrombin for 5 minutes induced phosphorylation of Akt, Erk and p38 (Figure 1), 
intracellular signaling molecules involved in PAR-mediated signaling. Already 0.01 unit/ml 
thrombin induced phosphorylation of these signaling molecules. Incubation with dabigatran 
inhibited this phosphorylation. 
Inflammation
Thrombin exposure, for 24 hr, induced expression of interleukin-6 (IL6) (Figure 2a) and 
monocyte chemotactic protein-1 (MCP-1) (Figure 2b) in atrial fibroblasts. These responses 
were repressed by dabigatran.
Fibrosis
Fibroblast stimulation with thrombin increased mRNA expression of smooth muscle 
actin (Figure 3a), which is indicative of differentiation towards active fibroblasts, i.e. 
myofibroblasts. In addition, expression of TGFβ1 (Figure 3b) was increased. 3H-proline 
incorporation (Figure 3c) was dose-dependently increased with thrombin, indicating 



























































































































































Figure 1: Thrombin induces phosphorylation of Erk (n = 6-7), Akt (n = 7-8) and p38 (n = 5-6) and 
dabigatran could attenuate these effects. Data are expressed as means ± SEM. * P < 0.05, ** P < 0.01, 
and *** P < 0.001 compared with control; # P < 0.05, ## P < 0.01, and ### P < 0.001 compared with 























































































































Figure 2: Thrombin dose-dependently increases expression of A) IL-6 (n = 8-13) and B) MCP-1 (n = 
8-12) and dabigatran reduced these effects. Data are expressed as means ± SEM. IL6, interleukin-6; 
MCP-1, monocyte chemoattractant protein-1. * P < 0.05, ** P < 0.01, and *** P < 0.001 compared with 
control; # P < 0.05, ## P < 0.01, and ### P < 0.001 compared with thrombin only.
Proliferation
Thrombin did not induce proliferation, i.e. an increase in cell number, in these adult 
fibroblasts, the positive control in this assay, fetal calf serum did induce proliferation (Figure 
4).
Receptor dependency
Figure 5a shows that the PAR1 receptor antagonists, RWJ56110 and SCH79797, and ATAP-2, 
a PAR1 blocking antibody, attenuate the response of thrombin and Trap-14, a PAR1 agonist, 
on proline incorporation. Gene expression induced by Trap-14 is similar to the response 
induced by thrombin (Figure 5b). In addition, PAR1 mRNA expression is upregulated when 
the cells are stimulated with thrombin (Figure 5c), indicating a positive feedback mechanism. 
Dabigatran attenuated this response. This suggests that the response induced by thrombin 















































































































































































Figure 3: Thrombin increased expression of genes associated with differentiation towards 
myofibroblasts and fibrosis A) smooth muscle actin (n = 8-15), B) TGFβ1 (n = 8-15) and increased 
incorporation of C) 3H-proline (n = 4-13). Dabigatran could prevent these effects, except for the highest 
dosage of thrombin for smooth muscle actin and 3H-proline. Data are expressed as means ± SEM. * P 
< 0.05, ** P < 0.01, and *** P < 0.001 compared with control; # P < 0.05, ## P < 0.01, and ### P < 0.001 













































































Figure 4: Thrombin did not induce proliferation (n = 3-7). Data are expressed as means ± SEM. 
















































































































Figure 5: The response induced by thrombin is dependent on PAR1. A) 3H-proline incorporation was 
reduced with PAR1 specific antagonists (n = 2-7). B) 10 μM Trap-14 induced gene-expression (n = 3), C) 
mRNA expression of PAR1 upon stimulation with thrombin (n = 8-11) and the effects of concomitant 
incubation with dabigatran. Data are expressed as means ± SEM. * P < 0.05 and *** P < 0.001 compared 















































In NRAM thrombin slightly increased 3H-leucine incorporation, this is an indication of 
increased protein synthesis and hypertrophy. In NRVM this increase did not reach statistical 
significance (Figure 6a). Gene expression of ANP, BNP and skeletal α-actin, markers of 
cardiomyocyte hypertrophy, were unchanged with thrombin stimulation, in contrast to 
































































































Figure 6: The effect of thrombin on hypertrophy related changes in neonatal rat cardiomyocytes A) The 
effect of thrombin (n = 7) on protein synthesis. B) The effect of thrombin (n = 6) on gene expression 
of ANP, BNP and skeletal α-actin in neonatal rat atrial cardiomyocytes (NRAM) and C) neonatal rat 
ventricular cardiomyocytes (NRVM). PE, phenylephrine 20 μM. Data are expressed as means ± SEM. * 














































In goats with AF the effectiveness of treatment with nadroparin, targeting Factor Xa and 
thrombin, on the remodeling process was investigated. Thrombin generation was 55.4% 
lower in the goats treated with nadroparin compared to the untreated animals. In addition, 
the coagulation potential was 75.2% lower in the nadroparin group than in the untreated 
animals. 
Already after 4 weeks of treatment, a protective effect of nadroparin treatment 
against the development of a substrate for AF was clearly detectable (Figure 7). The 
maximal activation time differences measured with a 256 channel mapping electrode (a 
commonly used measure for conduction heterogeneity and block)24 were 33% shorter in 
the nadroparin group (Control: 23.3 ± 3.1 ms, nadroparin: 15.7 ± 2.1 ms, p < 0.05). There 
was no change in atrial refractoriness or AF cycle length, indicating that not electrical but 
structural alterations might be responsible for the reduced AF complexity in the presence 
of nadroparin. In line with this hypothesis, we found that the cell-cell distances a (an early 
marker for atrial fibrosis)22 was approximately 50% lower (p < 0.01) in the nadroparin group 
while the cell width was unchanged.
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Figure 7: Effect of nadroparin on the development of a substrate for AF. Top: 256 channel mapping 
electrode, the maximal activation time differences, and AF cycle length. Bottom: hematoxylin and 















































The present study shows that thrombin induces adult atrial fibroblast activation, including 
activation of PAR-mediated signaling, proinflammatory effects, profibrotic effects and 
differentiation towards myofibroblasts. No proliferation was observed. Effects seemed 
to be dependent on PAR1-mediated signaling. In neonatal cardiomyocytes hypertrophy 
was not observed. Importantly, effects of thrombin could be attenuated with dabigatran. 
Nadroparin, targeting Factor Xa and thrombin, could reduce AF conduction time in goats 
with AF. In addition, cell-cell distance, an early marker of fibrosis, was reduced when animals 
were treated with nadroparin.
In atrial fibroblast, we observed profibrotic and proinflammatory effects of thrombin. 
Also in fibroblasts isolated from other tissues, such as kidney and lung, as well as in cardiac 
fibroblasts, a pro-fibrotic response upon stimulation with thrombin has been observed.25-28 
A role for PAR1 mediated signaling is suggested. We observed that Trap-14, a PAR1 
agonist, induced a response similar to the response induced by thrombin. In addition, 
we found that PAR1 blockade attenuated the increase in thrombin-induced proline 
incorporation. This is supported by activation of Akt, Erk and p38, which are involved in PAR-
signaling. Interestingly, Snead et al. demonstrated that PAR1 was the most highly expressed 
G-protein coupled receptor (GPCR) in cardiac fibroblasts, out of 190 expressed GPCRs.28 In 
cardiac fibroblasts, Sonin et al. also observed that the PAR1 antagonist SCH79797 reduced 
thrombin induced fibroblast activation, including phosphorylation of Erk, TGFβ production 
and myofibroblast transformation.27 Snead et al. demonstrated PAR1 dependence of the 
thrombin induced profibrotic response via knockdown of PAR1.28 In vivo, PAR1 deficient mice 
showed attenuation of inflammation and fibrosis in a model of lung fibrosis.29 Moreover, 
mice deficient in PAR1 performed better after ischemia-reperfusion injury compared to 
their wildtype littermates, although PAR1 deficiency could not reduce infarct size.12 PAR1 
antagonists are also capable of attenuating disease, including liver fibrosis, and LV remodeling 
upon ischemia-reperfusion in rats.15,27 In addition, PAR1 inhibition by SCH79797 reduced 
infarct size in an ischemia-reperfusion model in rats.30 These data suggest a protective effect 
of PAR1 blockade.
We observed no effects of thrombin on proliferation. In earlier studies proliferation has 
been shown in neonatal fibroblasts.11 In adult cardiac fibroblast thrombin caused pro-fibrotic 
effects, but no proliferation was observed.28 The latter is in agreement with our findings, and 
might represent a difference between neonatal and adult rat fibroblasts.
In the neonatal cardiomyocytes we obtained no evidence for hypertrophic effects of 
thrombin. In earlier studies thrombin has been shown to increase intracellular Ca2+-levels,10,31 
prolong action potential duration, augment cesium-induced early after depolarizations32 
and increase ventricular arrhythmias in reperfusion experiments in intact rat hearts.33 
In addition, in these previous studies, cellular hypertrophy was suggested.7,34 The main 
difference between our study and these previous studies is the different amount of thrombin 













































fibroblasts, we already observed changes induced by low levels of thrombin, i.e. 0.01 U/ml. 
Until recently, patients with AF mostly receive vitamin K antagonists (VKAs) to reduce 
the risk of stroke. VKAs inhibit proper formation of vitamin K-dependent coagulation factors 
(prothrombin, factors VII, IX, and X, protein C and protein S). These improperly formed 
coagulation factors do not bind to the cell membrane, thereby attenuating coagulation.35,36 
Interestingly, membrane binding does not seem necessary for activation of PARs by 
coagulation factors.37 Therefore, these improperly formed coagulation factors might still be 
able to activate PAR-mediated signaling. 
Recently, new oral anticoagulants (NOACs) have become available as an alternative to 
vitamin K antagonists. NOACs directly inhibit thrombin (dabigatran) or Factor Xa (rivaroxaban, 
apixaban) and could possibly inhibit both coagulation and PAR activation. Therefore, we 
used dabigatran to directly block thrombin-induced effects. All thrombin-induced responses 
could be attenuated with 350 ng/ml dabigatran, which is within the therapeutic range used 
in patients. An anti-fibrotic effect of dabigatran was also shown in lung fibroblasts which 
were stimulated with thrombin.13 In animal studies, direct inhibition of thrombin or Factor 
Xa seems to attenuate disease in a wide range of animal models, such as bleomycin-induced 
lung fibrosis,38,39 pulmonary hypertension in rats40 and atherosclerosis in mice.41
Our results in the goats demonstrate that nadroparin, inhibiting mainly Factor Xa but 
also inhibiting thrombin, can partially prevent the development of atrial fibrosis related to 
AF. Along with this, the complexity of AF was lower in the nadroparin goats compared to the 
control animals. These data strongly support the hypothesis that not only hypercoagulability 
produces atrial fibrosis during AF but also that inhibition of hypercoagulability may prevent 
the development of an AF substrate by inhibiting atrial fibrosis formation. 
In summary, thrombin induced a profibrotic and proinflammatory response in adult atrial 
fibroblasts, in the absence of proliferation. This was dependent on PAR1-mediated signaling. 
This suggests that activated coagulation is related to atrial remodeling and could contribute 
to the development of a substrate for AF. AF goats treated with nadroparin showed 
lower AF complexity. In addition, nadroparin could partially prevent the development of 
fibrosis related to AF. These observations are particularly interesting as NOACs have been 
demonstrated to effectively inhibit PAR-stimulation. Future studies will have to address the 
question whether anticoagulants can also effectively protect the atria of patients with AF 
against fibrosis.
Limitations
Fibroblasts in culture differentiate rapidly into myofibroblasts.42,43 For this reason we used 
fibroblasts from a low passage, however we observed that a large part of our cells expressed 















































The hypercoagulable state as occurs during AF causes pro-fibrotic and pro-inflammatory 
responses in cardiac fibroblasts. In goats with AF, targeting Factor Xa and thrombin with 
nadroparin attenuated atrial fibrosis and the complexity of the AF substrate. This suggests 
that inhibition of coagulation might prevent the development of a substrate for AF.
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